Figure 10

The dose response curve showing the in vitro inhibitory activity of the synthesized PVP SeNPs against the five tested carcinoma cell lines. (A) liver carcinoma (HepG2) cell line; (B) breast carcinoma (MCF-7) cell line; (C) colorectal carcinoma (Caco2) cell line; (D) cervix carcinoma (HeLa) cell line; (E) prostate carcinoma (PC3) cell line. The data are expressed as mean ± S.D.